Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2004

01-07-2004 | Laboratory Investigation

Pharmacokinetics and safety of intravitreally delivered etanercept

Authors: Sascha Fauser, Hubert Kalbacher, Nils Alteheld, Kan Koizumi, Tim U. Krohne, Antonia M. Joussen

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2004

Login to get access

Abstract

Background

The anti-inflammatory drug etanercept may be an effective therapeutic agent in diabetic retinopathy. In order to further evaluate its potential, the pharmacokinetics and safety of this drug after intravitreal delivery were investigated.

Methods

After intravitreal administration of etanercept in rabbits, clinical examination, electroretinography (ERG), visually evoked potentials (VEP) and histology were evaluated. The pharmacokinetics and distribution of etanercept were analyzed using fluorescence-coupled protein at 0, 2, 4, and 8 weeks after injection in vitreous, retina, and choroid.

Results

No adverse effects and signs of toxicity were found. Etanercept showed peak concentrations after 4 weeks in the retina and choroid.

Conclusions

Intravitreally delivered etanercept is safe and results in high concentrations in the retina and choroid over a long period of time.
Literature
1.
go back to reference Agabeyoglu IT, Wagner JG, Kay DR (1980) A sensitive high-pressure liquid chromatographic method for the determination of prednisone, prednisolone and hydrocortisone in plasma. Res Commun Chem Pathol Pharmacol 28:163–176PubMed Agabeyoglu IT, Wagner JG, Kay DR (1980) A sensitive high-pressure liquid chromatographic method for the determination of prednisone, prednisolone and hydrocortisone in plasma. Res Commun Chem Pathol Pharmacol 28:163–176PubMed
2.
go back to reference Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20:152–157 Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20:152–157
3.
go back to reference Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41:1153–1158PubMed Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41:1153–1158PubMed
4.
go back to reference Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH (2003) Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci 44:2112–2117CrossRefPubMed Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH (2003) Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci 44:2112–2117CrossRefPubMed
5.
go back to reference Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP (2001) Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147–152PubMed Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP (2001) Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147–152PubMed
6.
go back to reference Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K (1993) Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol 231:109–114PubMed Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K (1993) Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol 231:109–114PubMed
7.
go back to reference Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC (1996) Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80:168–173PubMed Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC (1996) Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80:168–173PubMed
8.
go back to reference Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A, Kociok N, Kirchhof B, Joussen AM. (2003) Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184–2191CrossRefPubMed Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A, Kociok N, Kirchhof B, Joussen AM. (2003) Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184–2191CrossRefPubMed
9.
go back to reference Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J (1999) Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol 115:409–414PubMed Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J (1999) Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol 115:409–414PubMed
10.
go back to reference Limb GA, Webster L, Soomro H, Janikoun S, Shilling J (1999) Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol 118:213–218CrossRefPubMed Limb GA, Webster L, Soomro H, Janikoun S, Shilling J (1999) Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol 118:213–218CrossRefPubMed
11.
go back to reference Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP (1999) VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40:1808–1812PubMed Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP (1999) VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40:1808–1812PubMed
12.
go back to reference McLeod DS, Lefer DJ, Merges C, Lutty GA (1995) Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 147:642–653PubMed McLeod DS, Lefer DJ, Merges C, Lutty GA (1995) Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 147:642–653PubMed
13.
go back to reference Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont A, Aiello LP, Ogura Y, Adamis AP (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836–10841PubMed Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont A, Aiello LP, Ogura Y, Adamis AP (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836–10841PubMed
14.
go back to reference Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415–417PubMed Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415–417PubMed
15.
go back to reference Scholes GN, O’Brien WJ, Abrams GW, Kubicek MF (1985) Clearance of triamcinolone from vitreous. Arch Ophthalmol 103:1567–1569PubMed Scholes GN, O’Brien WJ, Abrams GW, Kubicek MF (1985) Clearance of triamcinolone from vitreous. Arch Ophthalmol 103:1567–1569PubMed
16.
go back to reference Schröder S, Palinski W, Schmid-Schönbein GW (1991) Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81–100PubMed Schröder S, Palinski W, Schmid-Schönbein GW (1991) Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81–100PubMed
17.
go back to reference Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A (1995) [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin 90:134–137PubMed Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A (1995) [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin 90:134–137PubMed
18.
go back to reference Tano Y, Sugita G, Abrams G, Machemer R (1980) Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 89:131–136PubMed Tano Y, Sugita G, Abrams G, Machemer R (1980) Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 89:131–136PubMed
Metadata
Title
Pharmacokinetics and safety of intravitreally delivered etanercept
Authors
Sascha Fauser
Hubert Kalbacher
Nils Alteheld
Kan Koizumi
Tim U. Krohne
Antonia M. Joussen
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2004
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-004-0895-x

Other articles of this Issue 7/2004

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2004 Go to the issue